Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | SCN1A | P35498 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2983140 | 0.95 | HPGD (0.68) | RAB9ANPC1ALDH1A1USP2HPGD | |
| SCHEMBL183199 | 0.92 | LTA4H (0.59) | RAB9ANPC1ALDH1A1USP2HPGD | |
| SCHEMBL3140286 | 0.91 | RAB9A (0.72) | RAB9ANPC1ALDH1A1USP2HPGD | |
| SCHEMBL3165031 | 0.86 | HRH3 (0.67) | ALDH1A1HRH3KCNH2HRH1 | |
| SCHEMBL2180987 | 0.85 | HRH3 (0.70) | HRH3KCNH2HRH1 | |
| SCHEMBL19091219 | 0.83 | RAB9A (0.79) | RAB9ANPC1ALDH1A1USP2HPGD | |
| SCHEMBL3149847 | 0.83 | RAB9A (0.61) | RAB9ANPC1ALDH1A1USP2HPGD | |
| SCHEMBL1442766 | 0.82 | HRH3 (0.69) | ALDH1A1USP2HRH3HTR2AMAPK1 | |
| SCHEMBL1282683 | 0.82 | HRH3 (0.65) | ALDH1A1HRH3HRH1LTA4H | |
| SCHEMBL3131129 | 0.82 | RAB9A (0.60) | RAB9ANPC1HRH3DRD3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-07 | — | — | US | claimed |
| WO-2010014798-A2 | PYRIMIDOTRIAZINEDIONES AND PYRIMIDOPYRIMIDINEDIONES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-02-04 | — | — | WO | claimed |
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| EP-1630165-B1 | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | NIPPON KAYAKU KK (JP) | 2010-03-31 | — | — | EP | disclosed |
| WO-2010014798-A2 | PYRIMIDOTRIAZINEDIONES AND PYRIMIDOPYRIMIDINEDIONES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-02-04 | — | — | WO | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-7511065-B2 | Mixed lineage kinase modulators | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1630165-A1 | [1,2,4 ]TRIAZOLO [1,5-A]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2006-03-01 | — | — | EP | disclosed |
| EP-1567528-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004048383-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | RAB9A 1475/4885NPC1 1668/4885ALDH1A1 208/4885 |
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | TCF4, TCF7L2, CTNNB1 | RAB9A 3233/4885NPC1 28/4885ALDH1A1 1526/4885 |
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | MYLK2, CSNK1G2, CSNK1A1 | RAB9A 1942/4885NPC1 2787/4885ALDH1A1 3779/4885 |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | DPYD, TYMP, DHFR | RAB9A 4134/4885NPC1 1594/4885ALDH1A1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.